MNPR compared with IVVD: revenue, margins and what each company keeps, and the suppliers and customers both name

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

Compare

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MNPR 2

AZNAstraZenecasupplier

—NorthStarunlistedsupplier

Shared 0

No shared counterparties.

Only IVVD 9

—Undisclosed specialty distributor customerunlistedcustomer

—Adimabunlistedsupplier

—WuXi Biologicsunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—WuXi Biologics (Hong Kong)unlistedsupplier

5 more · IVVD chain ›

MNPRMonopar Therapeutics

68.60▼−5.78%· post 68.60· delayed

Mkt cap$488.7MRevenue—Revenue—

IVVDInvivyd, Inc.

0.58▼−8.05%· post 0.58· delayed

After hoursNov 5 '26delayed

Mkt cap$186.8MRevenue$14MQ2 FY26Revenue$53MFY25

Compare

After hoursNov 5 '26delayed

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

68.60▼−5.78%post 68.60delayed

Price

0.58▼−8.05%post 0.58delayed

$488.7M

Mkt cap

$186.8M

—

Revenue

$14MQ2 FY26

—

Revenue

$53MFY25

MNPR68.60▼−5.78%vsIVVD0.58▼−8.05%After hoursNov 5 '26delayed